MetaVia, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $8.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason McCarthy has given his Buy rating due to a combination of factors tied to MetaVia’s lead asset, DA-1726, and the company’s financial position. He views DA-1726 as a differentiated obesity therapy because its dual action on GLP-1 and glucagon receptors is designed to both curb appetite and boost energy expenditure, which may translate into faster weight loss and better preservation of lean mass than many current GLP-1–based approaches.
He also highlights early clinical results as highly encouraging, noting that short-duration dosing has already produced meaningful reductions in body weight and waist circumference with a relatively benign gastrointestinal profile and no study-related discontinuations. With new titration cohorts in the ongoing Phase 1 Part 3 study, an extended 16-week dosing window, and cash runway into late 2026, McCarthy believes upcoming data could significantly increase the program’s visibility in the obesity market and create upside for MTVA shares.
McCarthy covers the Healthcare sector, focusing on stocks such as Moleculin Biotech, Gain Therapeutics, and MetaVia. According to TipRanks, McCarthy has an average return of -15.8% and a 28.26% success rate on recommended stocks.
In another report released on March 27, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.